Cannabidiol enhances verbal episodic memory in healthy young participants: A randomized clinical trial

Hotz, Janine; Fehlmann, Bernhard; Papassotiropoulos, Andreas; Quervain, Dominique J-F de; Schicktanz, Nathalie

doi:10.1016/j.jpsychires.2021.09.007

Cited by 17 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An open-label trial of 200 mg daily CBD over 10 weeks found better verbal learning and memory performance at end of treatment compared to baseline (Solowij et al 2018); however, that trial lacked a placebo group so this effect could reflect practice on the task. A single-dose placebo-controlled trial of 12 mg CBD e-liquid improved verbal memory performance compared to placebo (Hotz et al 2021). The sample size of both trials was small (n = 20; n = 34), and the effect size for the difference in performance was also small across both studies (0.53, 0.028).…”

Section: Discussionmentioning

confidence: 94%

“…Clinical trial data provide preliminary evidence that CBD may benefit cognitive performance. A randomised trial in healthy participants of single-dose vaporised CBD e-liquid (12.5 mg CBD) found better verbal episodic memory performance (but not attention or working memory) after acute CBD administration compared to placebo (Hotz et al 2021). A trial of 6-week oral daily 1000 mg CBD treatment in people with psychosis found an improvement in the motor speed domain of a cognitive test battery compared to a placebo (McGuire et al 2018).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

Lees

Hines

Hindocha³

et al. 2023

Psychopharmacology

View full text Add to dashboard Cite

Rationale Chronic cannabis use is associated with impaired cognitive function. Evidence indicates cannabidiol (CBD) might be beneficial for treating cannabis use disorder. CBD may also have pro-cognitive effects; however, its effect on cognition in people with cannabis use disorder is currently unclear. Objectives We aimed to assess whether a 4-week CBD treatment impacted cognitive function. We hypothesised that CBD treatment would improve cognition from baseline to week 4, compared to placebo. Methods Cognition was assessed as a secondary outcome in a phase 2a randomised, double-blind, parallel-group and placebo-controlled clinical trial of 4-week daily 200 mg, 400 mg and 800 mg CBD for the treatment of cannabis use disorder. Participants had moderate or severe DSM-5 cannabis use disorder and intended to quit cannabis use. Our pre-registered primary cognitive outcome was delayed prose recall. Secondary cognitive outcomes were immediate prose recall, stop signal reaction time, trail-making task performance, verbal fluency and digit span. Results Seventy participants were randomly assigned to placebo (n = 23), 400 mg CBD (n = 24) and 800 mg CBD (n = 23). A 200 mg group was eliminated from the trial because it was an inefficacious dose at interim analysis (n = 12) and was not analysed here. For the primary cognitive outcome, there was no effect of CBD compared to placebo, evidenced by a lack of dose-by-time interaction at 400 mg (0.46, 95%CIs: − 1.41, 2.54) and 800 mg (0.89, 95%CIs: − 0.99, 2.81). There was no effect of CBD compared to placebo on secondary cognitive outcomes, except backwards digit span which increased following 800 mg CBD (0.30, 95%CIs: 0.02, 0.58). Conclusions In this clinical trial for cannabis use disorder, CBD did not influence delayed verbal memory. CBD did not have broad cognitive effects but 800 mg daily treatment may improve working memory manipulation. Clinical trial registration The trial was registered with ClinicalTrials.gov (NCT02044809) and the EU Clinical Trials Register (2013–000,361-36).

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

Lees

Hines

Hindocha³

et al. 2023

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The authors conclude that adverse effects specific to cognitive and driving performance were similar for THC-dominant cannabis and THC/CBD equivalent cannabis and, in some cases, CBD may worsen THC-induced impairment. Another placebo-controlled randomized trial reported enhanced verbal episodic memory performance among those administered cannabidiol as compared to the placebo, while also indicating that CBD may not impact attention or working memory performance negatively as no significant effects were found for those outcomes [ 159 ]. Health effects associated with cannabis vaping among youth and young adults are summarized in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

Cannabis Vaping Among Youth and Young Adults: a Scoping Review

et al. 2022

View full text Add to dashboard Cite

Purpose of Review The purpose of this review was to describe the state-of-the-literature on research specific to cannabis vaping among youth and young adults. Recent Findings Out of 1801 records identified, a total of 202 articles met eligibility criteria for inclusion in this review. Most of this literature (46.0% of studies) was specific to the health effects of cannabis vaping, particularly EVALI (e-cigarette and vaping associated lung injury). Other research areas identified in the review included the etiology (24.3%) and epidemiology (24.8%) of cannabis vaping, in addition to articles on regulation (8.4%) and marketing (5.5%) of the same. Summary Cannabis vaping is increasingly common among youth and young adults and more prevalent is settings where recreational use for adults has been legalized. The literature documents a number of negative health effects of cannabis vaping for young people, along with risk factors and reasons for the same.

show abstract

“…( Almog, et al, 2020 ; Birnbaum, et al, 2019 ; Efron, et al, 2021 ; Freeman, et al, 2020 ; Grimison, et al, 2020 ; Hotz, et al, 2021 ; Hurd, et al, 2019 ; Izgelov, et al, 2020 ; Lintzeris, et al, 2020 ; Mitelpunkt, et al, 2019 ; O'Neill, et al, 2021 ; Perkins, et al, 2020 ; Pretzsch, et al, 2019a ; Pretzsch, et al, 2019c ; Wall, et al, 2019 ; Xu, et al, 2020 ; Yassin, et al, 2019 ; Zylla, et al, 2021 )…”

Section: Resultsunclassified

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

et al. 2022

View full text Add to dashboard Cite

Cannabis has long been regarded as a recreational substance in the Western world. The recent marketing authorization of some medicinal products of industrial origin and the introduction onto the market of inflorescences for medical use mean that medical doctors can now prescribe Cannabis-based medicines in those countries which allow it. Nevertheless, there is still considerable controversy on this topic in the scientific community. In particular, this controversy concerns: the plant species to be used; the pathologies that can be treated and consequently the efficacy and safety of use; the routes of administration; the methods of preparation; the type and dosage of cannabinoids to be used; and, the active molecules of interest. As such, although medical Cannabis has been historically used, the results of currently completed and internationally published studies are inconclusive and often discordant. In light of these considerations, the aim of this work is to analyse the current legislation in countries that allow the use of medical Cannabis, in relation to the impact that this legislation has had on clinical trials. First of all, a literature search has been performed (PubMed and SciFinder) on clinical trials which involved the administration of Cannabis for medical use over the last 3 years. Of the numerous studies extrapolated from the literature, only about 43 reported data on clinical trials on medical Cannabis, with these mainly being performed in Australia, Brazil, Canada, Denmark, Germany, Israel, Netherlands, Switzerland, the United Kingdom and the United States of America. Once the reference countries were identified, an evaluation of the legislation in relation to Cannabis for medical use in each was carried out via the consultation of the pertinent scientific literature, but also of official government documentation and that of local regulatory authorities. This analysis provided us with an overview of the different legislation in these countries and, consequently, allowed us to analyse, with greater awareness, the results of the clinical trials published in the last 3 years in order to obtain general interest indications in the prosecution of scientific research in this area.

show abstract

Cannabidiol enhances verbal episodic memory in healthy young participants: A randomized clinical trial

Cited by 17 publications

References 34 publications

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

Cannabis Vaping Among Youth and Young Adults: a Scoping Review

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

Contact Info

Product

Resources

About